<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0198457</article-id>
<article-id pub-id-type="publisher-id">PONE-D-17-39432</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive system</subject><subj-group><subject>Gastrointestinal tract</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Digestive system</subject><subj-group><subject>Gastrointestinal tract</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Clinical genetics</subject><subj-group><subject>Genetic diseases</subject><subj-group><subject>Autosomal recessive diseases</subject><subj-group><subject>Cystic fibrosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Developmental biology</subject><subj-group><subject>Fibrosis</subject><subj-group><subject>Cystic fibrosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Cystic fibrosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Microbial genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial genomics</subject><subj-group><subject>Microbiome</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Pseudomonas aeruginosa</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Pseudomonas aeruginosa</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Pseudomonas</subject><subj-group><subject>Pseudomonas aeruginosa</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Gut bacteria</subject><subj-group><subject>Clostridium difficile</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Gut bacteria</subject><subj-group><subject>Bifidobacterium</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Experimental organism systems</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Escherichia coli</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Model organisms</subject><subj-group><subject>Escherichia coli</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Escherichia coli</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Bacterial pathogens</subject><subj-group><subject>Escherichia coli</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Enterobacteriaceae</subject><subj-group><subject>Escherichia</subject><subj-group><subject>Escherichia coli</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Gut bacteria</subject><subj-group><subject>Escherichia</subject><subj-group><subject>Escherichia coli</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Experimental organism systems</subject><subj-group><subject>Prokaryotic models</subject><subj-group><subject>Escherichia coli</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis</article-title>
<alt-title alt-title-type="running-head">Intestinal microbiota composition in patients with cystic fibrosis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>de Freitas</surname>
<given-names>Maiara Brusco</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9060-2288</contrib-id>
<name name-style="western">
<surname>Moreira</surname>
<given-names>Emilia Addison Machado</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Funding acquisition</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<role content-type="http://credit.casrai.org/">Project administration</role>
<role content-type="http://credit.casrai.org/">Supervision</role>
<role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tomio</surname>
<given-names>Camila</given-names>
</name>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Moreno</surname>
<given-names>Yara Maria Franco</given-names>
</name>
<role content-type="http://credit.casrai.org/">Conceptualization</role>
<role content-type="http://credit.casrai.org/">Data curation</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Daltoe</surname>
<given-names>Felipe Perozzo</given-names>
</name>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Barbosa</surname>
<given-names>Eliana</given-names>
</name>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Ludwig Neto</surname>
<given-names>Norberto</given-names>
</name>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Buccigrossi</surname>
<given-names>Vittoria</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Guarino</surname>
<given-names>Alfredo</given-names>
</name>
<role content-type="http://credit.casrai.org/">Formal analysis</role>
<role content-type="http://credit.casrai.org/">Methodology</role>
<xref ref-type="aff" rid="aff005"><sup>5</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Graduate Program in Nutrition, Federal University of Santa Catarina, Florianópolis, Brazil</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Nutrition, Graduate Program in Nutrition, Federal University of Santa Catarina, Florianópolis, Brazil</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Pathology, Federal University of Santa Catarina, Florianópolis, Brazil</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Joana de Gusmão Children´s Hospital, Santa Catarina, Florianópolis, Brazil</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Department of Translational Medical Science, Section of Pediatrics, University of Naples Federico II, Naples, Italy</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Palaniyar</surname>
<given-names>Nades</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Hospital for Sick Children, CANADA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">emilia.moreira@ufsc.br</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>13</volume>
<issue>6</issue>
<elocation-id>e0198457</elocation-id>
<history>
<date date-type="received">
<day>6</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>de Freitas et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0198457"/>
<abstract>
<p>The aim of the present study was to evaluate the effect of cystic fibrosis and antibiotic therapy on intestinal microbiota composition and intestinal inflammation in children and adolescents. A cross-sectional controlled study was conducted with 36 children and adolescents: 19 in the cystic fibrosis group (CFG) and 17 in the control group (CG) matched for age and sex. The CFG was subdivided based on the use of antibiotic therapy (CFAB group) and non-use of antibiotic therapy (CFnAB group). The following data were evaluated: colonization, antibiotic therapy, mutation, breastfeeding, use of infant formula, type of delivery, introduction of solid foods, body mass index, fecal calprotectin and intestinal microbiota composition (fluorescence <italic>in situ</italic> hybridization). Intestinal inflammation evaluated by fecal calprotectin was significantly higher in the CFG (median: 40.80 µg/g, IQR: 19.80–87.10, p = 0.040) and CFAB group (median: 62.95 µg/g, IQR: 21.80–136.62, p = 0.045) compared to the CG (median: 20.15 µg/g, IQR: 16.20–31.00), and the <italic>Bacteroides</italic>, Firmicutes, <italic>Eubacterium rectale</italic> and <italic>Faecalibacterium prausnitzii</italic> were significantly decreased (p &lt; 0.05) in the CFG compared to the CG, whereas the bacteria <italic>Clostridium difficile</italic>, <italic>Escherichia coli</italic> and <italic>Pseudomonas aeruginosa</italic> were significantly increased in the CFG (p &lt; 0.05). The main differences were found between the CG and CFAB group for <italic>Eubacterium rectale</italic> (p = 0.006), <italic>Bifidobacterium</italic> (p = 0.017), <italic>Escherichia coli</italic> (p = 0.030), Firmicutes (p = 0.002), <italic>Pseudomonas aeruginosa</italic> (p &lt; 0.001) and <italic>Clostridium difficile</italic> (p = 0.006). The results of this study confirm intestinal inflammation in patients with CF, which may be related to changes in the composition of the intestinal microbiota.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)</institution>
</funding-source>
<award-id>471197/2013-0</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9060-2288</contrib-id>
<name name-style="western">
<surname>Moreira</surname>
<given-names>Emilia Addison Machado</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>We thank the National Council for Scientific and Technological Development (CNPq) - Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for their financial support (#471197/2013-0) and scholarships for EAMM (#304281/2012-3); Programa de Bolsas de Estudo da Educação Superior de Santa Catarina (UNIEDU) for scholarships to MBF.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="4"/>
<page-count count="14"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information file.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Microbiome acquisition begins in the uterus and progresses during childhood. The composition of the microbiota is influenced by the type of delivery, feeding, exposure to antibiotics in the perinatal period and maternal physical contact [<xref ref-type="bibr" rid="pone.0198457.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0198457.ref002">2</xref>]. An increase in the diversity of the intestinal microbiota occurs beginning at birth and children one to three years of age have a pattern similar to that found in adults. However, the occurrence of infection results in a lower diversity of microbiota [<xref ref-type="bibr" rid="pone.0198457.ref003">3</xref>, <xref ref-type="bibr" rid="pone.0198457.ref004">4</xref>]. In addition to being associated with health promotion, breast milk provides significant amounts of <italic>Bifidobacterium</italic> and <italic>Lactobacillus</italic> [<xref ref-type="bibr" rid="pone.0198457.ref005">5</xref>] and the ingestion of solid foods may or may not exert a positive influence on the microbiome, depending on the type of food [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>].</p>
<p>The defect in the cystic fibrosis transmembrane regulator in patients with cystic fibrosis (CF) can have manifestations in the gastrointestinal tract, such as gastroesophageal reflux, viscous intestinal mucus due to dehydration, acidification of the medium, altered mucosal glycosylation [<xref ref-type="bibr" rid="pone.0198457.ref007">7</xref>], distal intestinal obstruction, inflammation, bacterial overgrowth in the small intestine, slow transit time, inflammatory bowel disease [<xref ref-type="bibr" rid="pone.0198457.ref008">8</xref>] and dysbiosis [<xref ref-type="bibr" rid="pone.0198457.ref009">9</xref>], the latter of which can trigger the overgrowth of opportunistic pathogens and contribute to the development of diseases [<xref ref-type="bibr" rid="pone.0198457.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0198457.ref011">11</xref>].</p>
<p>The mechanism underlying the inflammatory bowel process remains unclear, but inflammation in evidenced by the increase in inflammatory markers, such as calprotectin and rectal nitric oxide, in patients with CF [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0198457.ref012">12</xref>]. The use of antibiotics, such as tobramycin and erythromycin, is another factor that may influence the microbiota of the gastrointestinal tract [<xref ref-type="bibr" rid="pone.0198457.ref011">11</xref>]. While the ecological balance is normally restored within a few weeks after antibiotic ingestion, there is evidence that antibiotic-associated disorders may persist for a long time after treatment. Thus, prolonged exposure to antibiotics may result in the overgrowth of antibiotic-resistant bacteria [<xref ref-type="bibr" rid="pone.0198457.ref013">13</xref>], as <italic>Clostridium difficile</italic> (<italic>C</italic>. <italic>difficile</italic>), which can cause severe diarrhea and/or pseudomembranous colitis [<xref ref-type="bibr" rid="pone.0198457.ref014">14</xref>].</p>
<p>Studies have shown that patients with CF typically have decreased amounts of <italic>Bifidobacterium</italic> spp. [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>], the <italic>Bacteroides-Prevotella</italic> group [<xref ref-type="bibr" rid="pone.0198457.ref012">12</xref>], <italic>Clostridium</italic> cluster XIVa [<xref ref-type="bibr" rid="pone.0198457.ref015">15</xref>], <italic>Faecalibacterium prausnitzii</italic> (<italic>F</italic>. <italic>prausnitzii</italic>) [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>] and <italic>Eubacterium rectale</italic> (<italic>E</italic>. <italic>rectale</italic>) [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>], whereas <italic>Enterobacteriaceae</italic> and <italic>Clostridia</italic> [<xref ref-type="bibr" rid="pone.0198457.ref014">14</xref>] are increased.</p>
<p>The clinical relevance of the change in intestinal microorganisms is not well established, but the microflora of the gastrointestinal tract is known to be related to metabolic functions, such as the regulation of host immune response. Thus, the frequent use of antibiotics can have a negative cumulative effect on the metabolism and immune system in this population [<xref ref-type="bibr" rid="pone.0198457.ref016">16</xref>].</p>
<p>The aim of the present study was to evaluate the effect of CF and antibiotic therapy on intestinal microbiota composition and intestinal inflammation in children and adolescents.</p>
</sec>
<sec id="sec002">
<title>Methods and subjects</title>
<sec id="sec003">
<title>Study design</title>
<p>A cross-sectional study was conducted between March and December 2016 at the Joana de Gusmão Children’s Hospital in the city of Florianópolis, Brazil. This study received approval from the Human Research Ethics Committees of the hospital and the Federal University of Santa Catarina (certificate number: 48959715.2.1001.0121). The legal guardians of the children and adolescents signed a statement of informed consent.</p>
</sec>
</sec>
<sec id="sec004">
<title>Subjects</title>
<p>The required sample size calculated by the difference in means was 18 for each group (OpenEpi<sup>®</sup> program, 1:1 proportion of exposed to non-exposed, 80% power and 95% confidence level). Thus, the overall sample was composed of 36 children and adolescents. The control group (CG) was composed of 17 individuals with a median age of 3.00 years [interquartile range (IQR): 0.60–7.00 years] and cystic fibrosis group (CFG) was composed of 19 individuals with a median age of 4.00 years (IQR: 1.10–9.50 years). Moreover, the CFG was subdivided based on the use of antibiotic therapy (CFAB group) and non-use of antibiotic therapy (CFnAB group).</p>
<p>The inclusion criteria for the CFG were a diagnosis of CF (chloride sweat test ≥ 60 mmol/L) and clinical stability for at least 30 days prior to the data collection process [<xref ref-type="bibr" rid="pone.0198457.ref017">17</xref>]. The individuals in the CG were recruited from children’s care clinic of the hospital and matched to the CFG for age and sex, with a body mass index (BMI) in the ideal range and the absence of CF [<xref ref-type="bibr" rid="pone.0198457.ref017">17</xref>]. The following were the exclusion criteria for the CG: fever, trauma, diseases (celiac, respiratory, inflammatory, intestinal, rheumatic, psychiatric, degenerative, cardiovascular, diabetes mellitus, renal, primary or secondary immunodeficiency and glucose/lactose intolerance) and use of antibiotics, hormones, non-hormonal anti-inflammatory drugs, proton pump inhibitors, oral, inhaled and intravenous corticosteroids, ranitidine hydrochloride, immunosuppressants and antihistamines 30 days prior to the data collection. The exclusion criteria for the CFG were the same as those for the CG, except for the use of antibiotics. Patients taking antibiotics (colimycin, azithromycin, tobramycin, cefuroxime, ciprofloxacin, oxacillin and ceftazidime) for the treatment of lung disease were admitted to the study. Daily supplementation as part of the protocol was taken into account and supplement intake was determined on the basis of patient reports. The hospital medical protocol prescribed the following supplements: SourceCF<sup>®</sup> vitamin supplement (Eurand Pharmaceuticals, Huntsville, AL, USA) for those aged ≥ 1 year to &lt; 4 years, 2 mL/day; ADEK<sup>®</sup> (Axcan Pharma, Birmingham, AL, USA) at a dose of one tablet/day for those aged ≥ 4 to &lt; 10 years and two tablets/day for those aged ≥ 10 years [<xref ref-type="bibr" rid="pone.0198457.ref018">18</xref>]; CREON<sup>®</sup> (Solvay Pharmaceuticals, GmbH, Germany) for older children and adults, who require 500 to 4000 lipase units per gram of fat ingested (mean = 1800 lipase units/g of fat) [<xref ref-type="bibr" rid="pone.0198457.ref019">19</xref>].</p>
<sec id="sec005">
<title>Assessment of clinical characteristics, BMI, lung function and disease severity</title>
<p>Data on age, sex, date of birth, date of diagnosis of CF, colonization, antibiotic treatment and mutation were collected from the patients’ medical records. Information on breastfeeding, the use of an infant formula, type of delivery and the introduction of solid foods was based on parental reports. Anthropometric data (height and weight) were collected using the method described by Pereira [<xref ref-type="bibr" rid="pone.0198457.ref017">17</xref>]. BMI was classified based on the World Health Organization criteria [<xref ref-type="bibr" rid="pone.0198457.ref020">20</xref>] using the Anthro and AnthroPlus programs (WHO, Geneva, Switzerland). Bacteriological findings and lung function [assessed based on forced expiratory volume in one second (FEV<sub>1</sub>)] were determined as described by Pereira [<xref ref-type="bibr" rid="pone.0198457.ref017">17</xref>]. Disease severity was determined based on the Shwachman-Kulczycki (S-K) score [<xref ref-type="bibr" rid="pone.0198457.ref017">17</xref>].</p>
</sec>
<sec id="sec006">
<title>Analysis of intestinal inflammation</title>
<p>For the analysis of fecal calprotectin, feces were collected in plastic containers and delivered directly to the hospital. Intestinal inflammation was assessed based on fecal calprotectin, which was measured using the RIDASCREEN<sup>®</sup> Calprotectin (R-biopharm-AG) immunoenzyme test. Samples with a calprotectin concentration of 0 to 50 µg/g were considered normal, values between 50 to 100 µg/g were considered intermediate and values higher than 100 µg/g were considered indicative of intestinal inflammation [<xref ref-type="bibr" rid="pone.0198457.ref021">21</xref>].</p>
</sec>
<sec id="sec007">
<title>Fluorescence <italic>in situ</italic> hybridization</title>
<p>A plastic straw measuring 4 cm in length and 3 mm in diameter was introduced 4 to 10 mm into the feces for the collection of the sample, which was placed in a 50-mL Falcon, fixed with 30 mL of Carnoy’s solution composed of ethanol, glacial acetic acid and chloroform (6/6/1, respectively) (Dinâmica Química Contemporânea Ltda<sup>®</sup>) for 24 hours at room temperature and then kept refrigerated at 4°C until analysis [<xref ref-type="bibr" rid="pone.0198457.ref022">22</xref>].</p>
<p>Fecal samples fixed in Carnoy’s solution were embedded in paraffin, cut longitudinally into 4-µm sections, placed on SuperFrost slides (<italic>Thermo Scientific</italic>, Italy) and dewaxed with xylene and ethanol (VWR Chemicals, United Kingdom). The samples were then incubated with a hybridization solution (20 Mm Tris-HCL, 0.9 M NaCL, 0.1% SDS and 1% formamide at pH 7.4) with 100 ng of EUB mix of positive control oligonucleotide probes (EUB I, EUB II and EUB III) [<xref ref-type="bibr" rid="pone.0198457.ref022">22</xref>]. The slides were incubated with hybridization buffer with 25 ng of their respective FISH probes for 45 min at 50 ºC, visualized and quantified using a Nikon 80i Eclipse epifluorescence microscope with a Nikon DS-U2 color camera and the NIS-Element imaging software (Nikon, Tokyo, Japan) [<xref ref-type="bibr" rid="pone.0198457.ref022">22</xref>]. Bacteria with uneven distribution or a low overall concentration were enumerated within areas larger than 100 x 100 μm in whole microscopic fields or on the total surface of the fecal cylinder. All counts were performed at a magnification of 1000 times. The conversion of numbers within microscopic areas defined for bacterial concentrations per milliliter was based on the calculation that a sample of 10 μL with a cell concentration of 10<sup>7</sup> cells/mL has an average of 40 cells per field [<xref ref-type="bibr" rid="pone.0198457.ref022">22</xref>]. The samples were analyzed using the Eub338 mix probe conjugated with fluorescein isothiocyanate (FITC, green signal) at the 5’ end (positive control) [<xref ref-type="bibr" rid="pone.0198457.ref023">23</xref>] and a species-specific probe was conjugated with a single fluorescent carbocyanine molecule (Cy3, red signal). All probes were purchased from MWG Eurofins Operon (Ebersberg, Germany).</p>
</sec>
<sec id="sec008">
<title>Statistical analysis</title>
<p>Data with non-Gaussian distribution (determined using the Shapiro-Wilk test) were submitted to logarithmic normalization prior to the multiple linear regression analyzes. Differences between the CG and CFG regarding the variables used for characterization were analyzed using Student's t-test, Mann-Whitney test and chi-square test when categorical. Associations among antibiotic use, intestinal inflammation and intestinal microorganisms in the CG and CF groups were evaluated using multiple linear regression analysis adjusted for sex and age. Spearman’s rank correlation coefficients were calculated considering the CG and CFG separately to determine correlations among BMI, intestinal microorganisms and intestinal inflammation. Statistical analysis was performed with the aid of the SPSS program, version 16.0 for Windows<sup>TM</sup>, with a p-value &lt; 0.05 considered indicative of statistical significance.</p>
</sec>
</sec>
<sec id="sec009" sec-type="results">
<title>Results</title>
<sec id="sec010">
<title>Demographic characteristics, clinical markers, intestinal inflammation and intestinal microbiota</title>
<p>The participants were matched for sex and age, with no difference between the CG and CFG groups (p &gt; 0.05). However, the CFnAB group was composed of younger patients compared to the other groups (<xref ref-type="table" rid="pone.0198457.t001">Table 1</xref>). Delivery was by cesarean birth in the majority of the CFG (73.7%) and vaginal birth in the majority of the CG (52.9%). Based on the supplementation protocols, only one patient in the CFG did not supplement with pancreatic enzymes during the study. Most patients were exclusively breastfed for less than six months (CG: 76.5%; CFG: 73.7%), which explains the frequent use of infant formulas (around 70% in both groups) and the introduction of solid foods before six months of age (<xref ref-type="table" rid="pone.0198457.t001">Table 1</xref>). No significant difference was found between the CG and CFG regarding BMI, which suggests that CF does not affect nutritional status (p = 0.186) (<xref ref-type="table" rid="pone.0198457.t001">Table 1</xref>). In the stratified CFG, however, the CFnAB group had a higher mean BMI compared to the CFAB group (17.32 ± 2.19 kg/m² <italic>vs</italic>. 15.03 ± 0.92 kg/m², p = 0.011), despite being composed mainly of younger patients (<xref ref-type="table" rid="pone.0198457.t001">Table 1</xref>). The majority of patients with CF had the Phe508del mutation (ΔF508) (68.4%); one patient did not have this mutation and the remaining patients were not diagnosed during the study (<xref ref-type="table" rid="pone.0198457.t001">Table 1</xref>). The disease severity score and lung function in the CFG were classified as excellent (88.57 points) and good (80.67%), respectively. About 40% of the patients in the CFG had pulmonary colonization, 15.8% of whom were colonized by <italic>P</italic>. <italic>aeruginosa</italic> (<xref ref-type="table" rid="pone.0198457.t001">Table 1</xref>) and about 25% were colonized by <italic>Staphylococcus aureus</italic> and <italic>Burkholderia cepacia</italic>. These results are in line with the fact that about 50% were using antibiotics (colimicin, azithromycin, tobramycin, cefuroxime, ciprofloxacin, oxacillin, ceftazidime) during the study (<xref ref-type="table" rid="pone.0198457.t001">Table 1</xref>).</p>
<table-wrap id="pone.0198457.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0198457.t001</object-id>
<label>Table 1</label> <caption><title>Demographic and clinical markers of the control group (CG), cystic fibrosis group CFG), cystic fibrosis antibiotic therapy (CFAB) and cystic fibrosis absence of antibiotic therapy (CFnAB).</title></caption>
<alternatives>
<graphic id="pone.0198457.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="center"/>
<th align="left">CG<break/>(n = 17)</th>
<th align="left">CFG<break/>(n = 19)</th>
<th align="left">p-value<xref ref-type="table-fn" rid="t001fn008"><sup>4</sup></xref></th>
<th align="left">CFAB<break/>(n = 10)</th>
<th align="left">CFnAB<break/>(n = 9)</th>
<th align="left">p-value<xref ref-type="table-fn" rid="t001fn009"><sup>5</sup></xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" style="background-color:#F2F2F2">Age<xref ref-type="table-fn" rid="t001fn002"><sup>1</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t001fn005"><sup>€</sup></xref></td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">3.00 (0.6–7.0)</td>
<td align="left" style="background-color:#F2F2F2">4.00 (1.1–9.5)</td>
<td align="left" style="background-color:#F2F2F2">0.552</td>
<td align="left" style="background-color:#F2F2F2">6.00 (3.2–10.0)</td>
<td align="left" style="background-color:#F2F2F2">1.50 (0.8–7.0)</td>
<td align="left" style="background-color:#F2F2F2">0.447</td>
</tr>
<tr>
<td align="left">Sex n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t001fn006"><sup>£</sup></xref></td>
<td align="left">Male</td>
<td align="left">11 (64.7)</td>
<td align="left">10 (52.6)</td>
<td align="left">0.317</td>
<td align="left">03 (30.0)</td>
<td align="left">07 (77.8)</td>
<td align="left">0.051</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Female</td>
<td align="left">06 (35.3)</td>
<td align="left">09 (47.4)</td>
<td align="left"/>
<td align="left">07 (70.0)</td>
<td align="left">02 (22.2)</td>
<td align="left">Fisher</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2">Type of delivery n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t001fn006"><sup>£</sup></xref></td>
<td align="left" style="background-color:#F2F2F2">Vaginal</td>
<td align="left" style="background-color:#F2F2F2">09 (52.9)</td>
<td align="left" style="background-color:#F2F2F2">05 (26.3)</td>
<td align="left" style="background-color:#F2F2F2">0.237</td>
<td align="left" style="background-color:#F2F2F2">02 (20.0)</td>
<td align="left" style="background-color:#F2F2F2">03 (33.3)</td>
<td align="left" style="background-color:#F2F2F2">0.628</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">Cesarean</td>
<td align="left" style="background-color:#F2F2F2">07 (41.2)</td>
<td align="left" style="background-color:#F2F2F2">14 (73.7)</td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">08 (80.0)</td>
<td align="left" style="background-color:#F2F2F2">06 (66.7)</td>
<td align="left" style="background-color:#F2F2F2"/>
</tr>
<tr>
<td align="left">Breastfeeding n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t001fn006"><sup>£</sup></xref></td>
<td align="left">&lt; 6 months</td>
<td align="left">13 (76.5)</td>
<td align="left">14 (73.7)</td>
<td align="left"><bold>0.003</bold></td>
<td align="left">07 (70.0)</td>
<td align="left">07 (77.8)</td>
<td align="left">0.701</td>
</tr>
<tr>
<td align="left"/>
<td align="left">≥ 6 months</td>
<td align="left">04 (23.5)</td>
<td align="left">05 (26.3)</td>
<td align="left"/>
<td align="left">03 (30.0)</td>
<td align="left">02 (22.2)</td>
<td align="left"/>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2">Infant formula n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t001fn006"><sup>£</sup></xref></td>
<td align="left" style="background-color:#F2F2F2">No</td>
<td align="left" style="background-color:#F2F2F2">05 (29.4)</td>
<td align="left" style="background-color:#F2F2F2">05 (26.3)</td>
<td align="left" style="background-color:#F2F2F2">0.836</td>
<td align="left" style="background-color:#F2F2F2">03 (30.0)</td>
<td align="left" style="background-color:#F2F2F2">02 (22.2)</td>
<td align="left" style="background-color:#F2F2F2">0.701</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">Yes</td>
<td align="left" style="background-color:#F2F2F2">12 (70.6)</td>
<td align="left" style="background-color:#F2F2F2">14 (73.7)</td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">07 (70.0)</td>
<td align="left" style="background-color:#F2F2F2">07 (77.8)</td>
<td align="left" style="background-color:#F2F2F2"/>
</tr>
<tr>
<td align="left">Starting solid foods n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t001fn006"><sup>£</sup></xref></td>
<td align="left">&lt; 6 months</td>
<td align="left">06 (35.3)</td>
<td align="left">11 (57.9)</td>
<td align="left">0.175</td>
<td align="left">06 (60.0)</td>
<td align="left">05 (55.6)</td>
<td align="left">0.845</td>
</tr>
<tr>
<td align="left"/>
<td align="left">≥ 6 months</td>
<td align="left">11 (64.7)</td>
<td align="left">08 (42.1)</td>
<td align="left"/>
<td align="left">04 (40.0)</td>
<td align="left">04 (44.4)</td>
<td align="left"/>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2">BMI (kg/m²)<xref ref-type="table-fn" rid="t001fn004"><sup>3</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="t001fn007"><sup>¥</sup></xref></td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">17.07 ± 1.38</td>
<td align="left" style="background-color:#F2F2F2">16.17 ± 2.01</td>
<td align="left" style="background-color:#F2F2F2">0.186</td>
<td align="left" style="background-color:#F2F2F2">15.03 ± 0.92</td>
<td align="left" style="background-color:#F2F2F2">17.32 ± 2.19</td>
<td align="left" style="background-color:#F2F2F2"><bold>0.011</bold></td>
</tr>
<tr>
<td align="left">Mutation n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref></td>
<td align="left">Homozygous Phe508del</td>
<td align="left">-</td>
<td align="left">06 (31.6)</td>
<td align="left">-</td>
<td align="left">04 (40.0)</td>
<td align="left">02 (22.2)</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Heterozygous Phe508del</td>
<td align="left">-</td>
<td align="left">07 (36.8)</td>
<td align="left">-</td>
<td align="left">04 (40.0)</td>
<td align="left">03 (33.3)</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Others</td>
<td align="left"/>
<td align="left">01 (5.3)</td>
<td align="left">-</td>
<td align="left">01 (10.0)</td>
<td align="left">-</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left"/>
<td align="left">No results</td>
<td align="left">-</td>
<td align="left"/>
<td align="left"/>
<td align="left">01 (10.0)</td>
<td align="left">04 (44.4)</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2">S-K score (points)</td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">88.57 ± 10.88</td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">87.50 ± 9.35</td>
<td align="left" style="background-color:#F2F2F2">89.38 ± 12.37</td>
<td align="left" style="background-color:#F2F2F2">0.762</td>
</tr>
<tr>
<td align="left">FEV<sub>1</sub> (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref></td>
<td align="left"/>
<td align="left">-</td>
<td align="left">80.67 ± 22.00</td>
<td align="left">-</td>
<td align="left">71.07 ± 25.19</td>
<td align="left">93.48 ± 8.34</td>
<td align="left">0.175</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2">Lung colonization, n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref></td>
<td align="left" style="background-color:#F2F2F2">Negative</td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">07 (36.8)</td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">01 (10.0)</td>
<td align="left" style="background-color:#F2F2F2">06 (66.7)</td>
<td align="left" style="background-color:#F2F2F2">-</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2"><italic>P</italic>. <italic>aeruginosa</italic></td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">03 (15.8)</td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">03 (30.0)</td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">-</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">Others</td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">05 (26.3)</td>
<td align="left" style="background-color:#F2F2F2">-</td>
<td align="left" style="background-color:#F2F2F2">03 (30.0)</td>
<td align="left" style="background-color:#F2F2F2">02 (22.2)</td>
<td align="left" style="background-color:#F2F2F2">-</td>
</tr>
<tr>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">No results</td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">04 (21.1)</td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2">03 (30.0)</td>
<td align="left" style="background-color:#F2F2F2">01 (11.1)</td>
<td align="left" style="background-color:#F2F2F2">-</td>
</tr>
<tr>
<td align="left">Antibiotic therapy, n (%)<xref ref-type="table-fn" rid="t001fn003"><sup>2</sup></xref></td>
<td align="left">No</td>
<td align="left">17 (100)</td>
<td align="left">09 (47.4)</td>
<td align="left">-</td>
<td align="left">-</td>
<td align="left">09 (47.4)</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left"/>
<td align="left">Yes</td>
<td align="left">-</td>
<td align="left">10 (52.6)</td>
<td align="left">-</td>
<td align="left">10 (52.6)</td>
<td align="left">-</td>
<td align="left">-</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>BMI: Body mass index; Shwachman-Kulczychi score: S-K escore. FEV1: Forced Expiratory Volume in the First Second. <italic>P</italic>. <italic>aeruginosa</italic>: <italic>Pseudomonas</italic> aeruginosa.</p></fn>
<fn id="t001fn002"><p><sup>1</sup>Values in median and interquartile interval.</p></fn>
<fn id="t001fn003"><p><sup>2</sup>Values in frequency and percentage.</p></fn>
<fn id="t001fn004"><p><sup>3</sup>Values in mean and standard desviation.</p></fn>
<fn id="t001fn005"><p><sup>€</sup>Performed Mann Whitney test.</p></fn>
<fn id="t001fn006"><p><sup>£</sup>Performed chi-square test.</p></fn>
<fn id="t001fn007"><p><sup>¥</sup>Performed Student's t-test.</p></fn>
<fn id="t001fn008"><p>p-value<sup>4</sup>: CG <italic>versus</italic> CFG.</p></fn>
<fn id="t001fn009"><p>p value<sup>5</sup>: CFAB <italic>versus</italic> CFnAB. Significance p-value &lt; 0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Fecal calprotectin (marker of intestinal inflammation) was significantly higher in CFG (median: 40.80 µg/g, IQR: 19.80–87.10 µg/g, p = 0.017) and CFAB group (median: 62.95 µg/g, IQR: 23.80–129.10 µg/g, p = 0.008) compared to the CG (median: 20.15 µg/g, IQR: 16.20–31.00) (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref> and <xref ref-type="table" rid="pone.0198457.t003">3</xref>). <italic>Bacteroides</italic>, Firmicutes, <italic>E</italic>. <italic>rectale</italic> and <italic>F</italic>. <italic>prausnitzii</italic> were significantly lower (p &lt; 0.05) in the CFG compared to the CG, whereas <italic>C</italic>. <italic>difficile</italic>, <italic>Escherichia coli</italic> (<italic>E</italic>. <italic>coli</italic>) and <italic>P</italic>. <italic>aeruginosa</italic> were significantly higher in the CFG (p &lt; 0.05) (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref> and <xref ref-type="table" rid="pone.0198457.t003">3</xref>). In the comparison of the two CF groups, only <italic>Bifidobacterium</italic> was significantly lower in the CFAB group compared to the CFnAB group (sex and age adjusted analyses, p = 0.015) (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref> and <xref ref-type="table" rid="pone.0198457.t004">4</xref>).</p>
<table-wrap id="pone.0198457.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0198457.t002</object-id>
<label>Table 2</label> <caption><title>Intestinal inflammation and intestinal microbiota of the control group (CG), cystic fibrosis group CFG), cystic fibrosis antibiotic therapy (CFAB-group) and cystic fibrosis absence of antibiotic therapy (CFnAB-group).</title></caption>
<alternatives>
<graphic id="pone.0198457.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="left">CG<break/>(n = 17)</th>
<th align="left">CFG<break/>(n = 19)</th>
<th align="left">CFAB<break/>(n = 10)</th>
<th align="left">CFnAB<break/>(n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="justify" style="background-color:#F2F2F2"><bold>Intestinal inflammatory markers</bold><xref ref-type="table-fn" rid="t002fn001"><sup><bold>#</bold></sup></xref></td>
<td align="justify" style="background-color:#F2F2F2"/>
<td align="justify" style="background-color:#F2F2F2"/>
<td align="justify" style="background-color:#F2F2F2"/>
<td align="justify" style="background-color:#F2F2F2"/>
</tr>
<tr>
<td align="justify">Fecal calprotectin (µg/g feces)</td>
<td align="left">20.15 (16.20–31.00)</td>
<td align="left">40.80 (19.80–87.10)</td>
<td align="left">62.95 (23.80–129.10)</td>
<td align="left">29.70 (10.40–52.20)</td>
</tr>
<tr>
<td align="justify" style="background-color:#F2F2F2"><bold>Intestinal microbiota</bold><xref ref-type="table-fn" rid="t002fn001"><sup><bold>#</bold></sup></xref></td>
<td align="justify" style="background-color:#F2F2F2"/>
<td align="justify" style="background-color:#F2F2F2"/>
<td align="justify" style="background-color:#F2F2F2"/>
<td align="justify" style="background-color:#F2F2F2"/>
</tr>
<tr>
<td align="justify"><italic>Bacteroides</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">28.30 (19.30–38.00)</td>
<td align="left">15.70 (1.10–24.65)</td>
<td align="left">2.92 (0.00–24.30)</td>
<td align="left">20.00 (2.83–25.00)</td>
</tr>
<tr>
<td align="justify"><italic>Bifidobacterium</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">20.30 (14.65–23.15)</td>
<td align="left">13.00 (5.52–21.20)</td>
<td align="left">5.51 (0.60–17.00)</td>
<td align="left">20.70 (13.00–22.30)</td>
</tr>
<tr>
<td align="justify"><italic>Veillonella</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.70 (0.00–11.35)</td>
<td align="left">1.00 (0.00–4.39)</td>
<td align="left">0.87 (0.00–1,77)</td>
<td align="left">1.00 (0.00–7.00)</td>
</tr>
<tr>
<td align="justify">Firmicutes (×10<sup>9</sup>/mL feces)</td>
<td align="left">9.33 (1.55–12.17)</td>
<td align="left">0.97 (0.77–1.57)</td>
<td align="left">0.98 (0.60–1.53)</td>
<td align="left">0.97 (0.77–1.63)</td>
</tr>
<tr>
<td align="justify"><italic>Eubacterium rectale</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">21.00 (16.00–23.00)</td>
<td align="left">10.70 (3.74–15.15)</td>
<td align="left">12.5 (1.17–18.00)</td>
<td align="left">10.30 (6.30–13.30)</td>
</tr>
<tr>
<td align="justify"><italic>Clostridium difficile</italic> (×10<sup>9</sup>/ml feces)</td>
<td align="left">0.20 (0.13–0.44)</td>
<td align="left">0.50 (0.34–1.02)</td>
<td align="left">0.54 (0.47–1,07)</td>
<td align="left">0.50 (0.30–0.93)</td>
</tr>
<tr>
<td align="justify"><italic>Lactobacillus paracasei</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">3.17 (2.02–8.47)</td>
<td align="left">2.37 (1.79–5.74)</td>
<td align="left">2.07 (1.40–5.00)</td>
<td align="left">2.77 (2.27–6.47)</td>
</tr>
<tr>
<td align="justify"><italic>Faecalibacterium prausnitzii</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">14.00 (3.92–27.65)</td>
<td align="left">1.00 (0.17–11.50)</td>
<td align="left">0.79 (0.00–4.43)</td>
<td align="left">1.90 (0.33–18.00)</td>
</tr>
<tr>
<td align="justify"><italic>Escherichia coli</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.67 (0.40–1.60)</td>
<td align="left">1.47 (1.02–2.67)</td>
<td align="left">1.79 (1.00–2.80)</td>
<td align="left">1.37 (1.27–2.50)</td>
</tr>
<tr>
<td align="justify"><italic>Pseudomonas aeruginosa</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.23 (0.15–0.53)</td>
<td align="left">1.13 (0.87–3.92)</td>
<td align="left">0.95 (0.70–1.93)</td>
<td align="left">2.27 (1.10–5.00)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p><sup>#</sup>Values presented in median and interquartile interval. Significance values of the comparisons between CG <italic>versus</italic> CF groups (CF, CFAB and CFnAB) and CFAB <italic>versus</italic> CFnAB were represented by the crude “p” values of the multiple linear regression analysis (95% confidence interval) in Tables <xref ref-type="table" rid="pone.0198457.t003">3</xref> and <xref ref-type="table" rid="pone.0198457.t004">4</xref>.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0198457.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0198457.t003</object-id>
<label>Table 3</label> <caption><title>Multiple linear regression analysis between control group (CG, n = 17) and cystic fibrosis group (CFG, n = 19), between CG (n = 17) and cystic fibrosis antibiotic therapy (CFAB-group), and between CG and cystic fibrosis absence of antibiotic therapy (CFnAB-group).</title></caption>
<alternatives>
<graphic id="pone.0198457.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Variables</th>
<th align="left" colspan="4">Cystic fibrosis group (n = 19)</th>
<th align="left" colspan="4">CFAB (n = 10)</th>
<th align="left" colspan="4">CFnAB (n = 9)</th>
</tr>
<tr>
<th align="left"/>
<th align="left">Crude<break/>β 0 coef.</th>
<th align="left">p-value</th>
<th align="left">Adjusted β 1 coef.</th>
<th align="left">p-value</th>
<th align="left">Crude<break/>β 0 coef.</th>
<th align="left">p-value</th>
<th align="left">Adjusted β 1 coef.</th>
<th align="left">p-value</th>
<th align="left">Crude<break/>β 0 coef.</th>
<th align="left">p-value</th>
<th align="left">Adjusted β 1 coef.</th>
<th align="left">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="13" style="background-color:#F2F2F2"><bold>Intestinal inflammatory markers</bold><xref ref-type="table-fn" rid="t003fn002"><sup><bold>#</bold></sup></xref></td>
</tr>
<tr>
<td align="left">Fecal calprotectin (µg/g feces)</td>
<td align="left">-0.384</td>
<td align="left"><bold>0.030</bold></td>
<td align="left">-0.377</td>
<td align="left"><bold>0.017</bold></td>
<td align="left">0.545</td>
<td align="left"><bold>0.007</bold></td>
<td align="left">0.543</td>
<td align="left"><bold>0.008</bold></td>
<td align="left">0.310</td>
<td align="left">0.161</td>
<td align="left">0.367</td>
<td align="left">0.064</td>
</tr>
<tr>
<td align="left" colspan="13" style="background-color:#F2F2F2"><bold>Intestinal microbiota</bold><xref ref-type="table-fn" rid="t003fn002"><sup><bold>#</bold></sup></xref></td>
</tr>
<tr>
<td align="left"><italic>Bacteroides</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.435</td>
<td align="left"><bold>0.021</bold></td>
<td align="left">0.430</td>
<td align="left"><bold>0.024</bold></td>
<td align="left">-0.495</td>
<td align="left"><bold>0.027</bold></td>
<td align="left">-0.479</td>
<td align="left">0.051</td>
<td align="left">-0.426</td>
<td align="left"><bold>0.048</bold></td>
<td align="left">-0.530</td>
<td align="left"><bold>0.015</bold></td>
</tr>
<tr>
<td align="left"><italic>Bifidobacterium</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.296</td>
<td align="left">0.095</td>
<td align="left">0.275</td>
<td align="left">0.131</td>
<td align="left">-0.529</td>
<td align="left"><bold>0.008</bold></td>
<td align="left">-0.531</td>
<td align="left"><bold>0.018</bold></td>
<td align="left">0.008</td>
<td align="left">0.969</td>
<td align="left">-0.008</td>
<td align="left">0.968</td>
</tr>
<tr>
<td align="left"><italic>Veillonella</italic><break/>(×10<sup>9</sup>/mL feces)</td>
<td align="left">0.028</td>
<td align="left">0.895</td>
<td align="left">0.031</td>
<td align="left">0.881</td>
<td align="left">-0.087</td>
<td align="left">0.733</td>
<td align="left">-0.143</td>
<td align="left">0.591</td>
<td align="left">0.046</td>
<td align="left">0.862</td>
<td align="left">0.062</td>
<td align="left">0.815</td>
</tr>
<tr>
<td align="left">Firmicutes<break/>(×10<sup>9</sup>/mL feces)</td>
<td align="left">0.633</td>
<td align="left"><bold>&lt;0.001</bold></td>
<td align="left">0.573</td>
<td align="left"><bold>&lt;0.001</bold></td>
<td align="left">-0.622</td>
<td align="left"><bold>0.001</bold></td>
<td align="left">-0.476</td>
<td align="left"><bold>0.002</bold></td>
<td align="left">-0.522</td>
<td align="left"><bold>0.009</bold></td>
<td align="left">-0.549</td>
<td align="left"><bold>0.001</bold></td>
</tr>
<tr>
<td align="left"><italic>Eubacterium rectale</italic><break/>(×10<sup>9</sup>/mL feces)</td>
<td align="left">0.364</td>
<td align="left"><bold>0.041</bold></td>
<td align="left">0.383</td>
<td align="left"><bold>0.034</bold></td>
<td align="left">-0.311</td>
<td align="left">0.130</td>
<td align="left">-0.299</td>
<td align="left">0.171</td>
<td align="left">-0.437</td>
<td align="left"><bold>0.033</bold></td>
<td align="left">-0.490</td>
<td align="left"><bold>0.026</bold></td>
</tr>
<tr>
<td align="left"><italic>Clostridium difficile</italic><break/>(×10<sup>9</sup>/mL feces)</td>
<td align="left">-0.384</td>
<td align="left"><bold>0.027</bold></td>
<td align="left">-0.419</td>
<td align="left"><bold>0.018</bold></td>
<td align="left">0.343</td>
<td align="left">0.094</td>
<td align="left">0.440</td>
<td align="left"><bold>0.048</bold></td>
<td align="left">0.379</td>
<td align="left">0.075</td>
<td align="left">0.347</td>
<td align="left">0.104</td>
</tr>
<tr>
<td align="left"><italic>Lactobacillus paracasei</italic><break/>(×10<sup>9</sup>/mL feces)</td>
<td align="left">0.108</td>
<td align="left">0.543</td>
<td align="left">0.130</td>
<td align="left">0.470</td>
<td align="left">-0.184</td>
<td align="left">0.378</td>
<td align="left">-0.340</td>
<td align="left">0.096</td>
<td align="left">-0.020</td>
<td align="left">0.924</td>
<td align="left">-0.008</td>
<td align="left">0.972</td>
</tr>
<tr>
<td align="left"><italic>Faecalibacterium prausnitzii</italic><break/>(×10<sup>9</sup>/mL feces)</td>
<td align="left">0.484</td>
<td align="left"><bold>0.009</bold></td>
<td align="left">0.592</td>
<td align="left"><bold>0.001</bold></td>
<td align="left">-0.592</td>
<td align="left"><bold>0.005</bold></td>
<td align="left">-0,737</td>
<td align="left"><bold>0.001</bold></td>
<td align="left">-0.383</td>
<td align="left">0.087</td>
<td align="left">-0.494</td>
<td align="left"><bold>0.020</bold></td>
</tr>
<tr>
<td align="left"><italic>Escherichia coli</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">-0.452</td>
<td align="left"><bold>0.006</bold></td>
<td align="left">-0.492</td>
<td align="left"><bold>0.002</bold></td>
<td align="left">0.472</td>
<td align="left"><bold>0.013</bold></td>
<td align="left">0.570</td>
<td align="left"><bold>0.004</bold></td>
<td align="left">0.395</td>
<td align="left"><bold>0.046</bold></td>
<td align="left">0.318</td>
<td align="left"><bold>0.049</bold></td>
</tr>
<tr>
<td align="left"><italic>Pseudomonas aeruginosa</italic><break/>(×10<sup>9</sup>/mL feces)</td>
<td align="left">-0.727</td>
<td align="left"><bold>&lt;0.001</bold></td>
<td align="left">-0.728</td>
<td align="left"><bold>&lt;0.001</bold></td>
<td align="left">0.686</td>
<td align="left"><bold>&lt;0.001</bold></td>
<td align="left">0.607</td>
<td align="left"><bold>0.001</bold></td>
<td align="left">0.785</td>
<td align="left"><bold>&lt;0.001</bold></td>
<td align="left">0.817</td>
<td align="left"><bold>&lt;0.001</bold></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>β coef.: beta coefficient; β 0 coefficient: crude values; β 1 coefficient: values adjusted for confounding variables (sex and age).</p></fn>
<fn id="t003fn002"><p><sup>#</sup> Values ​​were normalized by log<sub>10</sub> transformation.</p></fn>
<fn id="t003fn003"><p>“p-value” values were derived from the multiple linear regression analysis (95% confidence interval).</p></fn>
<fn id="t003fn004"><p>Boldface data indicate statistical significance (p-value &lt; 0.05).</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0198457.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0198457.t004</object-id>
<label>Table 4</label> <caption><title>Multiple linear regression analysis between cystic fibrosis antibiotic therapy (CFAB-group, n = 10) and cystic fibrosis absence of antibiotic therapy (CFnAB-group, n = 9).</title></caption>
<alternatives>
<graphic id="pone.0198457.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="justify">Variables</th>
<th align="left">Crude<break/>β 0 coef.</th>
<th align="left">p-value</th>
<th align="left">Adjusted<break/>β 1 coef.</th>
<th align="left">p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" style="background-color:#F2F2F2"><bold>Intestinal inflammatory markers</bold> <xref ref-type="table-fn" rid="t004fn002"><sup><bold>#</bold></sup></xref></td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2"/>
</tr>
<tr>
<td align="justify">Fecal calprotectin (µg/g feces)</td>
<td align="left">-0.321</td>
<td align="left">0.181</td>
<td align="left">-0.223</td>
<td align="left">0.320</td>
</tr>
<tr>
<td align="justify" style="background-color:#F2F2F2"><bold>Intestinal microbiota</bold> <xref ref-type="table-fn" rid="t004fn002"><sup><bold>#</bold></sup></xref></td>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2"/>
<td align="left" style="background-color:#F2F2F2"/>
</tr>
<tr>
<td align="justify"><italic>Bacteroides</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.076</td>
<td align="left">0.796</td>
<td align="left">-0.032</td>
<td align="left">0.932</td>
</tr>
<tr>
<td align="justify"><italic>Bifidobacterium</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.532</td>
<td align="left"><bold>0.028</bold></td>
<td align="left">0.725</td>
<td align="left"><bold>0.015</bold></td>
</tr>
<tr>
<td align="justify"><italic>Veillonella</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.153</td>
<td align="left">0.617</td>
<td align="left">0.368</td>
<td align="left">0.284</td>
</tr>
<tr>
<td align="justify">Firmicutes (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.271</td>
<td align="left">0.276</td>
<td align="left">0.234</td>
<td align="left">0.405</td>
</tr>
<tr>
<td align="justify"><italic>Eubacterium rectale</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">-0.013</td>
<td align="left">0.962</td>
<td align="left">-0.160</td>
<td align="left">0.656</td>
</tr>
<tr>
<td align="justify"><italic>Clostridium difficile</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.108</td>
<td align="left">0.669</td>
<td align="left">-0.019</td>
<td align="left">0.948</td>
</tr>
<tr>
<td align="justify"><italic>Lactobacillus paracasei</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.188</td>
<td align="left">0.454</td>
<td align="left">0.185</td>
<td align="left">0.543</td>
</tr>
<tr>
<td align="justify"><italic>Faecalibacterium prausnitzii</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.224</td>
<td align="left">0.442</td>
<td align="left">0.417</td>
<td align="left">0.119</td>
</tr>
<tr>
<td align="justify"><italic>Escherichia coli</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">-0.138</td>
<td align="left">0.572</td>
<td align="left">-0.169</td>
<td align="left">0.544</td>
</tr>
<tr>
<td align="justify"><italic>Pseudomonas aeruginosa</italic> (×10<sup>9</sup>/mL feces)</td>
<td align="left">0.291</td>
<td align="left">0.241</td>
<td align="left">0.375</td>
<td align="left">0.202</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>β coef.: beta coefficient; β 0 coefficient: crude values; β 1 coefficient: values adjusted for confounding variables (sex and age).</p></fn>
<fn id="t004fn002"><p><sup># </sup>Values ​​were normalized by log<sub>10</sub> transformation.</p></fn>
<fn id="t004fn003"><p>“p-values” were derived from the multiple linear regression analysis (95% confidence interval).</p></fn>
<fn id="t004fn004"><p>Boldface data indicate statistical significance (p-value &lt; 0.05).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec011">
<title>Associations between the use of antibiotics and both fecal calprotectin and intestinal microorganisms</title>
<p>In the multiple linear regression analysis of the use of antibiotics adjusted for sex and age, fecal calprotectin was significantly higher in the CFAB group (median: 62.95 μg/g feces, IQR: 21.80–136.63) compared to the CG (median: 20.15 μg/g feces, IQR: 16.20–31.00, p = 0.007) (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref> and <xref ref-type="table" rid="pone.0198457.t003">3</xref>), whereas no significant difference was found between the CFAB and CFnAB groups (sex and age adjusted analyses, p = 0.181) (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref>, <xref ref-type="table" rid="pone.0198457.t003">3</xref> and <xref ref-type="table" rid="pone.0198457.t004">4</xref>).</p>
<p>With regard to intestinal microorganisms, <italic>E</italic>. <italic>rectale</italic> and Firmicutes were significantly higher in the GC compared to both the CFAB (<italic>E</italic>. <italic>rectale</italic>: p = 0.027; Firmicutes: p = 0.002) and CFnAB (<italic>E</italic>. <italic>rectale</italic>: p = 0.003; Firmicutes: p = 0.004) groups, with no significant difference between the two CF groups (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref> and <xref ref-type="table" rid="pone.0198457.t003">3</xref>). <italic>Bifidobacterium</italic> was significantly lower in the CG compared to the CFAB group (p = 0.011), but no significant difference was found in comparison to the CFnAB group (p = 1.000) (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref> and <xref ref-type="table" rid="pone.0198457.t003">3</xref>). <italic>Bifidobacterium</italic> was the only microorganism analyzed that was significantly lower in the CFAB group than the CFnAB group (p = 0.010) (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref> and <xref ref-type="table" rid="pone.0198457.t004">4</xref>). <italic>C</italic>. <italic>difficile</italic> and <italic>P</italic>. <italic>aeruginosa</italic> were lower in the CG compared to both the CFAB (<italic>C</italic>. <italic>difficile</italic>: p = 0.001; <italic>P</italic>. <italic>aeruginosa</italic>: p = 0.001) and CFnAB (<italic>C</italic>. <italic>difficile</italic>: p = 0.033; <italic>P</italic>. <italic>aeruginosa</italic>: p &lt; 0.001) groups, with no significant difference between the two CF groups (Tables <xref ref-type="table" rid="pone.0198457.t002">2</xref>–<xref ref-type="table" rid="pone.0198457.t004">4</xref>).</p>
</sec>
<sec id="sec012">
<title>Correlations between intestinal microorganisms and both BMI and fecal calprotectin</title>
<p>A positive correlation was found between BMI and <italic>Bifidobacterium</italic> in the CFG (CFG: rho = 0.658, p = 0.003; CG: rho = 0.372, p = 0.234) (<xref ref-type="fig" rid="pone.0198457.g001">Fig 1C</xref>), whereas no significant correlations were found between BMI and other microorganisms (<xref ref-type="fig" rid="pone.0198457.g001">Fig 1</xref> and <xref ref-type="supplementary-material" rid="pone.0198457.s002">S2</xref> and <xref ref-type="supplementary-material" rid="pone.0198457.s004">S4</xref> Tables). Negative correlations were found between fecal calprotectin and both <italic>F</italic>. <italic>prausnitzii</italic> (CFG: rho = -0.478, p = 0.039; CG: rho = -0.014, p = 0.964) (<xref ref-type="fig" rid="pone.0198457.g002">Fig 2C</xref>) and <italic>L</italic>. <italic>paracasei</italic> (CFG: rho = -0.504, p = 0.028; CG = rho = -0.393, p = 0.184) (<xref ref-type="fig" rid="pone.0198457.g002">Fig 2D</xref>), whereas no significant correlations were found for other microorganisms. A positive correlation was found between Bacteroides and <italic>L</italic>. <italic>paracasei</italic> (CFG: rho = 0.503, p = 0.028; CG: rho = -0.184, p = 0.480) (supplementary material) and a negative correlation was found between <italic>Veillonella</italic> and <italic>E</italic>. <italic>rectale</italic> in the CFG (CFG: rho = , p = 0.027; CG: rho = 0.078, p = 0.766) (<xref ref-type="supplementary-material" rid="pone.0198457.s001">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0198457.s003">S3</xref> Tables).</p>
<fig id="pone.0198457.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0198457.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Correlation between body mass index (BMI) and intestinal microorganisms.Cystic fibrosis group (CFG), Control group (CG).*p &lt;0.05.</title>
<p>BMI: Body mass index. CFG: Cystic fibrosis group. CG: Control group.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.g001" xlink:type="simple"/>
</fig>
<fig id="pone.0198457.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0198457.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Correlation between fecal calprotectin and intestinal microorganisms in cystic fibrosis group (CFC) and control group (CG). * p &lt;0.05.</title>
<p>CFG: Cystic fibrosis group. CG: Control group. Spearman’s correlation, *p &lt; 0.05.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.g002" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec013" sec-type="conclusions">
<title>Discussion</title>
<p>The literature reports intestinal abnormalities in the microbiota of patients with CF [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0198457.ref012">12</xref>, <xref ref-type="bibr" rid="pone.0198457.ref024">24</xref>]. However, it is unclear whether this altered microbiota is the consequence of the disease or antibiotic therapy and the implications of these changes remain unknown. The present study shows a different pattern of bacterial species.</p>
<p>The patients in the CFG had a similar BMI to the volunteers in the CG as well as adequate lung function and an “excellent” disease severity score (≥ 86 points), although the majority had the ΔF508 mutation, which is associated with the impairment of lung function and a consequent worsening of nutritional status [<xref ref-type="bibr" rid="pone.0198457.ref025">25</xref>]. Pulmonary colonization by bacteria was found in about 40% of the CFG. Moreover, one of the patients did not present pulmonary colonization by <italic>P</italic>. <italic>aeruginosa</italic> at the collection time, but the bacterium was present in a large amount in the intestinal microbiota. About three months after the study, the patient exhibited pulmonary colonization by <italic>P</italic>. <italic>aeruginosa</italic>, which suggests that intestinal colonization may precede pulmonary colonization [<xref ref-type="bibr" rid="pone.0198457.ref026">26</xref>]. However, longitudinal studies are needed to confirm this assumption.</p>
<p>The positive correlation found between BMI and <italic>Bifidobacterium</italic> in the CFG shows that an improvement in nutritional status may be related to an increase of <italic>Bifidobacterium</italic>, which, together with <italic>Faecalibacterium</italic> and <italic>E</italic>. <italic>rectale</italic>, is regarded as a marker of healthy intestinal microbiota [<xref ref-type="bibr" rid="pone.0198457.ref015">15</xref>, <xref ref-type="bibr" rid="pone.0198457.ref027">27</xref>]. Decreased quantities of these bacteria can affect the nutrition of enterocytes and, consequently, the maintenance of intestinal health [<xref ref-type="bibr" rid="pone.0198457.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0198457.ref028">28</xref>]. After weaning, <italic>Bifidobacterium</italic> gradually decreases and <italic>Bacteroides</italic> and <italic>Eubacterium</italic> become predominant, but it is still considered a determinant of adult intestinal health [<xref ref-type="bibr" rid="pone.0198457.ref027">27</xref>]. <italic>Bifidobacterium</italic> was the only microorganism that was significantly decreased in the CFAB group compared to the CFnAB group, which may be related to the use of antibiotics.</p>
<p>With regard to breastfeeding, approximately 70% of both groups (CG and CFG) were exclusively breastfed for less than six months and the CFG had lower values of the phylum Firmicutes. Lactate-producing bacteria, such as <italic>Lactobacillus</italic>, and those that use lactate, such as bacteria belonging to the genera <italic>Veillonella</italic> and <italic>Faecalibacterium</italic> and the phylum Firmicutes, provide the host with important short-chain fatty acid metabolites, which are related to protection against intestinal inflammation [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0198457.ref029">29</xref>]. The intestinal microbiome develops throughout childhood, during which the assemblage is characterized by an increase in colonization by <italic>Bifidobacteria</italic> and microorganisms belonging to the phyla Firmicutes and Bacteroidetes as well as a reduction in <italic>Enterobacteria</italic>. Thus, any alteration in this colonization process leads to a change in the composition of the microbiota [<xref ref-type="bibr" rid="pone.0198457.ref030">30</xref>].</p>
<p>Fecal calprotectin is considered a good marker of intestinal inflammation [<xref ref-type="bibr" rid="pone.0198457.ref031">31</xref>] and was increased in the CFG (approximately 47% of the group had concentrations higher than 50 µg/g of feces). This is in agreement with data described in the literature [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0198457.ref012">12</xref>]. The negative correlation between fecal calprotectin and both <italic>F</italic>. <italic>prausnitzii</italic> and <italic>L</italic>. <italic>paracasei</italic> suggest that intestinal inflammation may be related to a reduction in these bacteria. <italic>F</italic>. <italic>prausnitzii</italic> is a butyrate-producing bacterium and the decrease in the production of this substance can exert an influence on both the nutritional status of enterocytes and luminal pH, consequently affecting the maintenance of intestinal health [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>]. <italic>Lactobacillus</italic> spp. are lactic acid-producing bacteria, which is reported to be associated with the prevention of respiratory infections [<xref ref-type="bibr" rid="pone.0198457.ref032">32</xref>]. In the analysis of the association between fecal calprotectin and the use of antibiotics, the influence of antibiotic therapy on the development of intestinal inflammation in CF was not clear. Although a difference was found between the CF groups, it was non-significant, which may be a consequence of the sample size.</p>
<p>In the present study, butyrate-producing (<italic>E</italic>. <italic>rectale</italic> and <italic>F</italic>. <italic>prausnitzii</italic>), lactic acid-producing (<italic>L</italic>. <italic>paracasei</italic> and <italic>Bifidobacterium</italic> spp.) and acetate-producing (<italic>Bacteroides</italic>) microorganisms were significantly lower and <italic>E</italic>. <italic>coli</italic>, <italic>C</italic>. <italic>difficile</italic> and <italic>P</italic>. <italic>aeruginosa</italic> were higher in the CFG compared to the CG, which is in agreement with data reported in the literature [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0198457.ref012">12</xref>, <xref ref-type="bibr" rid="pone.0198457.ref027">27</xref>]. In contrast, a previous study found no difference regarding <italic>Veillonella</italic> bacteria in the patients with cystic fibrosis [<xref ref-type="bibr" rid="pone.0198457.ref033">33</xref>].</p>
<p>The negative correlation between <italic>Veillonella</italic> and <italic>E</italic>. <italic>rectale</italic> and the positive correlation between <italic>Bacteroides</italic> and <italic>L</italic>. <italic>paracasei</italic> demonstrate a relationship among these microorganisms.</p>
<p>The microorganisms <italic>Bacteroides</italic>, <italic>E</italic>. <italic>rectale</italic>, <italic>F</italic>. <italic>prausnitzii</italic>, <italic>Bifidobacterium</italic> and Firmicutes were significantly lower in the CFAB group compared to the CG, whereas <italic>E</italic>. <italic>coli</italic>, <italic>C</italic>. <italic>difficile</italic> and <italic>P</italic>. <italic>aeruginosa</italic> were significantly higher in the CFAB group compared to the CG. It should be noted that these changes in the intestinal microbiota were also found in the CFnAB group.</p>
<p>Burk (2017) [<xref ref-type="bibr" rid="pone.0198457.ref024">24</xref>] found alterations in the intestinal microbiota of adults with CF, with an increase in the phylum Firmicutes and a decrease in <italic>Bacteriodes</italic>, which differs from the present findings. In contrast, Bruzzese (2014) [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>] found similar results to those of the present investigation in a study involving children with CF. This difference may be due to the methods employed as well as the difference in age, which consequently exerts an influence on the composition of the intestinal microbiota.</p>
<p>As previously reported in a study by Hoffman (2014) [<xref ref-type="bibr" rid="pone.0198457.ref034">34</xref>], <italic>E</italic>. <italic>coli</italic> was significantly increased in the CFG. In a study involving patients with CF aged 10 to 22 years, Miragoli (2017) [<xref ref-type="bibr" rid="pone.0198457.ref012">12</xref>] found an increase in <italic>E</italic>. <italic>coli</italic> in the group with CF, but the difference was non-significant in comparison to the control group. The increase in <italic>E</italic>. <italic>coli</italic> has been related to dysbiosis and the abundance of <italic>E</italic>. <italic>coli</italic> in patients with CF may be due to the decreased motility and/or accumulation of mucus [<xref ref-type="bibr" rid="pone.0198457.ref035">35</xref>]. Evidence suggests that changes in the intestinal lumen during an inflammatory process may increase the ability of <italic>E</italic>. <italic>coli</italic> to colonize the intestinal mucosa and induce further inflammation [<xref ref-type="bibr" rid="pone.0198457.ref034">34</xref>]. Hoffman (2017) [<xref ref-type="bibr" rid="pone.0198457.ref034">34</xref>] suggests that <italic>E</italic>. <italic>coli</italic> may serve as a marker and cause of gastrointestinal tract dysfunction and disease in this population.</p>
<p><italic>C</italic>. <italic>difficile</italic> is considered the major entero-pathogen of antibiotic-associated diarrhea and is responsible for cases of pseudomembranous colitis [<xref ref-type="bibr" rid="pone.0198457.ref036">36</xref>, <xref ref-type="bibr" rid="pone.0198457.ref037">37</xref>]. Indeed, this bacterium was found to be increased in the CFG and CFAB group in the present study.</p>
<p><italic>P</italic>. <italic>aeruginosa</italic> is considered the most aggressive bacterium with regard to pulmonary function in patients with CF. However, the occurrence and influence of this bacterium in the intestinal microbiota of this population has not previously been studied. One study found that <italic>P</italic>. <italic>aeruginosa</italic> was the most frequent species identified in the feces of patients with irritable bowel syndrome and may be involved in the pathophysiology of the disease [<xref ref-type="bibr" rid="pone.0198457.ref038">38</xref>], indicating that it may also be related to intestinal dysbiosis. The increase in <italic>P</italic>. <italic>aeruginosa</italic> in the intestinal microbiota and the fact that it preceded pulmonary colonization should be studied further to enable a better understanding of the mechanisms involved as well as the harm that it can cause.</p>
<p>The microorganisms evaluated herein were selected based on their influence on the maintenance of intestinal health and the relationship with CF reported in the literature [<xref ref-type="bibr" rid="pone.0198457.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0198457.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0198457.ref012">12</xref>, <xref ref-type="bibr" rid="pone.0198457.ref034">34</xref>]. Therefore, the failure to analyze the microbiota population as a whole should be considered a limitation of the present study. Other limitations are cross-sectional design, which does not enable inferences regarding cause and effect, and the small sample size. However, the results of the present study confirm the presence of intestinal inflammation in patients with CF and suggest that the disease may be related to changes in the colonization of some microorganisms. The frequent use of antibiotics does not appear to be closely related to the change in intestinal microbiota, but further studies are needed to reach such conclusions.</p>
</sec>
<sec id="sec014">
<title>Supporting information</title>
<supplementary-material id="pone.0198457.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.s001" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Spearman’s rank correlations between intestinal microorganisms in the cystic fibrosis group (n = 19).</title>
<p><italic>P</italic>. <italic>aeruginosa</italic>: <italic>Pseudomonas aeruginosa</italic>. <italic>E</italic>. <italic>rectale</italic>: <italic>Eubacterium rectale</italic>. <italic>F</italic>. <italic>prausnitzii</italic>: <italic>Faecalibacterium prausnitzii</italic>. <italic>L</italic>. <italic>paracasei</italic>: <italic>Lactobacillus paracasei</italic>. <italic>E</italic>. <italic>coli</italic>: <italic>Escherichia coli</italic>. <italic>C</italic>. <italic>difficile</italic>: <italic>Clostridium difficile</italic>. * Correlation is significant at the 0.05 level (2-tailed).</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0198457.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.s002" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Spearman’s rank correlations between intestinal microorganisms and fecal calprotectin and body mass index in the cystic fibrosis group.</title>
<p><italic>P</italic>.<italic>aeruginosa</italic>: <italic>Pseudomonas aeruginosa</italic>. <italic>E rectale</italic>: <italic>Eubacterium rectale</italic>. <italic>F</italic>. <italic>prausnitzii</italic>: <italic>Faecalibacterium prausnitzii</italic>. <italic>L</italic>. <italic>paracasei</italic>: <italic>Lactobacillus paracasei</italic>. <italic>E</italic>. <italic>coli</italic>: <italic>Escherichia coli</italic>. <italic>C</italic>. <italic>difficile</italic>: <italic>Clostridium difficile</italic>. F. Cal: Fecal Calprotectin (n = 19). BMI: body mass index (n = 18). *Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed).</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0198457.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.s003" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Spearman’s rank correlations between intestinal microorganisms in the control group (CG).</title>
<p><italic>P</italic>.<italic>aeruginosa</italic>: <italic>Pseudomonas aeruginosa</italic>. <italic>E rectale</italic>: <italic>Eubacterium rectale</italic>. <italic>F</italic>. <italic>prausnitzii</italic>: <italic>Faecalibacterium prausnitzii</italic>. <italic>L</italic>. <italic>paracasei</italic>: <italic>Lactobacillus paracasei</italic>. <italic>E</italic>. <italic>coli</italic>: <italic>Escherichia coli</italic>. <italic>C</italic>. <italic>difficile</italic>: <italic>Clostridium difficile</italic>. (n = 16)<sup>1</sup> - (n = 15)<sup>2</sup>. *Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed).</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0198457.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0198457.s004" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>Spearman’s rank correlations between intestinal microorganisms and fecal calprotectin (F. Cal.) and body mass index (BMI) in the control group (n = 19).</title>
<p><italic>P</italic>.<italic>aeruginosa</italic>: <italic>Pseudomonas aeruginosa</italic>. <italic>E rectale</italic>: <italic>Eubacterium rectale</italic>. <italic>F</italic>. <italic>prausnitzii</italic>: <italic>Faecalibacterium prausnitzii</italic>. <italic>L</italic>. <italic>paracasei</italic>: <italic>Lactobacillus paracasei</italic>. <italic>E</italic>. <italic>coli</italic>: <italic>Escherichia coli</italic>. <italic>C</italic>. <italic>difficile</italic>: <italic>Clostridium difficile</italic>. Fecal calprotectin: (n = 10)<sup>1</sup> (n = 12)<sup>2</sup>. BMI: (n = 10)<sup>1</sup> (n = 11)<sup>3</sup>. *Correlation is significant at the 0.05 level (2-tailed). **Correlation is significant at the 0.01 level (2-tailed).</p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank the National Council for Scientific and Technological Development–Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) in Brazil, Scholarship Program for Higher Education in Santa Catarina—Programa de Bolsas de Estudo da Educação Superior de Santa Catarina (UNIEDU) in Santa Catarina, Brazil, Coordination of Improvement of Higher Level Personnel—Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (<italic>CAPES</italic>) in Brazil, Joana de Gusmão Children´s Hospital, Brazil–Hospital Infantil Joana de Gusmão in Santa Catarina, Brazil, Associação Catarinense de Assistência ao Mucoviscidótico—Catarino's Association for Mucovisthiococcal Care in Santa Catarina, Brazil and Department of Translational Medical Science, section of Pediatrics, University of Naples Federico II, Naples, Italy.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0198457.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rautava</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Luoto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Salminen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Isolauri</surname> <given-names>E</given-names></name>. <article-title>Microbial contact during pregnancy, intestinal colonization and human disease</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2012</year>;<volume>9</volume>(<issue>10</issue>):<fpage>565</fpage>–<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrgastro.2012.144" xlink:type="simple">10.1038/nrgastro.2012.144</ext-link></comment> <object-id pub-id-type="pmid">22890113</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Berrington</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Stewart</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Embleton</surname> <given-names>ND</given-names></name>, <name name-style="western"><surname>Cummings</surname> <given-names>SP</given-names></name>. <article-title>Gut microbiota in preterm infants: assessment and relevance to health and disease</article-title>. <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2013</year>;<volume>98</volume>(<issue>4</issue>):<fpage>F286</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/archdischild-2012-302134" xlink:type="simple">10.1136/archdischild-2012-302134</ext-link></comment> <object-id pub-id-type="pmid">23009761</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Palmer</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bik</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>DiGiulio</surname> <given-names>DB</given-names></name>, <name name-style="western"><surname>Relman</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Brown</surname> <given-names>PO</given-names></name>. <article-title>Development of the human infant intestinal microbiota</article-title>. <source>PLoS Biol</source>. <year>2007</year>;<volume>5</volume>(<issue>7</issue>):<fpage>e177</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pbio.0050177" xlink:type="simple">10.1371/journal.pbio.0050177</ext-link></comment> <object-id pub-id-type="pmid">17594176</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yatsunenko</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Rey</surname> <given-names>FE</given-names></name>, <name name-style="western"><surname>Manary</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Trehan</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Dominguez-Bello</surname> <given-names>MG</given-names></name>, <name name-style="western"><surname>Contreras</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Human gut microbiome viewed across age and geography</article-title>. <source>Nature</source>. <year>2012</year>;<volume>486</volume>(<issue>7402</issue>):<fpage>222</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature11053" xlink:type="simple">10.1038/nature11053</ext-link></comment> <object-id pub-id-type="pmid">22699611</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pannaraj</surname> <given-names>PS</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Cerini</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Bender</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rollie</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Association between breast milk bacterial communities and establishment and development of the infant gut microbiome</article-title>. <source>JAMA Pediatr</source>. <year>2017</year>;<volume>171</volume>(<issue>7</issue>):<fpage>647</fpage>–<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamapediatrics.2017.0378" xlink:type="simple">10.1001/jamapediatrics.2017.0378</ext-link></comment> <object-id pub-id-type="pmid">28492938</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bruzzese</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Callegari</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Raia</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Viscovo</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Scotto</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Ferrari</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with lactobacillus GG: A randomised clinical trial</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>2</issue>):<fpage>e87796</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0087796" xlink:type="simple">10.1371/journal.pone.0087796</ext-link></comment> <object-id pub-id-type="pmid">24586292</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Norkina</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Burnett</surname> <given-names>TG</given-names></name>, <name name-style="western"><surname>De Lisle</surname> <given-names>RC</given-names></name>. <article-title>Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine</article-title>. <source>Infect Immun</source>. <year>2004</year>;<volume>72</volume>(<issue>10</issue>):<fpage>6040</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/IAI.72.10.6040-6049.2004" xlink:type="simple">10.1128/IAI.72.10.6040-6049.2004</ext-link></comment> <object-id pub-id-type="pmid">15385508</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lynch</surname> <given-names>SV</given-names></name>, <name name-style="western"><surname>Goldfarb</surname> <given-names>KC</given-names></name>, <name name-style="western"><surname>Wild</surname> <given-names>YK</given-names></name>, <name name-style="western"><surname>Kong</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>De Lisle</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Brodie</surname> <given-names>EL</given-names></name>. <article-title>Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota</article-title>. <source>Gut Microbes</source>. <year>2013</year>;<volume>4</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/gmic.22430" xlink:type="simple">10.4161/gmic.22430</ext-link></comment> <object-id pub-id-type="pmid">23060053</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Leach</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Katz</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Day</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Jaffe</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Ooi</surname> <given-names>CY</given-names></name>. <article-title>Update of faecal markers of inflammation in children with cystic fibrosis</article-title>. <source>Mediators Inflamm</source>. <year>2012</year>;2012. Article ID 948367, <fpage>6</fpage> p. <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2012/948367" xlink:type="simple">http://dx.doi.org/10.1155/2012/948367</ext-link>.</mixed-citation></ref>
<ref id="pone.0198457.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hawrelak</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Myers</surname> <given-names>SP</given-names></name>. <article-title>The causes of intestinal dysbiosis: A review</article-title>. <source>Altern Med Rev</source>. <year>2004</year>;<volume>9</volume>(<issue>2</issue>):<fpage>180</fpage>–<lpage>97</lpage>. <object-id pub-id-type="pmid">15253677</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dethlefsen</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Huse</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Sogin</surname> <given-names>ML</given-names></name>, <name name-style="western"><surname>Relman</surname> <given-names>DA</given-names></name>. <article-title>The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing</article-title>. <source>PLOS biology</source>. <year>2008</year>;<volume>6</volume>(<issue>11</issue>):<fpage>e280</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pbio.0060280" xlink:type="simple">10.1371/journal.pbio.0060280</ext-link></comment> <object-id pub-id-type="pmid">19018661</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miragoli</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Federici</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ferrari</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Minuti</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rebecchi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bruzzese</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota</article-title>. <source>FEMS microbiology ecology</source>. <year>2017</year>;<volume>93</volume>(<issue>2</issue>):<fpage>FIW230</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/femsec/fiw230" xlink:type="simple">10.1093/femsec/fiw230</ext-link></comment> <object-id pub-id-type="pmid">27810876</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Preidis</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Versalovic</surname> <given-names>J</given-names></name>. <article-title>Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>136</volume>(<issue>6</issue>):<fpage>2015</fpage>–<lpage>31</lpage>. <object-id pub-id-type="pmid">19462507</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hussain</surname> <given-names>SZ</given-names></name>, <name name-style="western"><surname>Chu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Greenberg</surname> <given-names>DP</given-names></name>, <name name-style="western"><surname>Orenstein</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>S</given-names></name>. <article-title>Clostridium difficile colitis in children with cystic fibrosis</article-title>. <source>Dig Dis Sci</source>. <year>2004</year>;<volume>49</volume>(<issue>1</issue>):<fpage>116</fpage>–<lpage>21</lpage>. <object-id pub-id-type="pmid">14992445</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Duytschaever</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Huys</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bekaert</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Boulanger</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>De Boeck</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Vandamme</surname> <given-names>P</given-names></name>. <article-title>Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota</article-title>. <source>Journal of Cystic Fibrosis</source>. <year>2013</year>;<volume>12</volume>(<issue>3</issue>):<fpage>206</fpage>–<lpage>15</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcf.2012.10.003" xlink:type="simple">10.1016/j.jcf.2012.10.003</ext-link></comment> <object-id pub-id-type="pmid">23151540</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lynch</surname> <given-names>SV</given-names></name>, <name name-style="western"><surname>Bruce</surname> <given-names>KD</given-names></name>. <article-title>The cystic fibrosis airway microbiome</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2013</year>;<volume>3</volume>(<issue>3</issue>):<fpage>a009738</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/cshperspect.a009738" xlink:type="simple">10.1101/cshperspect.a009738</ext-link></comment> <object-id pub-id-type="pmid">23457293</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pereira</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Moreira</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Bennemann</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Moreno</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Buss Zda</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Barbosa</surname> <given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Influence of inflammatory response, infection, and pulmonary function in cystic fibrosis</article-title>. <source>Life Sci</source>. <year>2014</year>;<volume>109</volume>(<issue>1</issue>):<fpage>30</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lfs.2014.06.002" xlink:type="simple">10.1016/j.lfs.2014.06.002</ext-link></comment> <object-id pub-id-type="pmid">24931908</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Borowitz</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Baker</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Stallings</surname> <given-names>V</given-names></name>. <article-title>Consensus report on nutrition for pediatric patients with cystic fibrosis</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2002</year>;<volume>35</volume>(<issue>3</issue>):<fpage>246</fpage>–<lpage>59</lpage>. <object-id pub-id-type="pmid">12352509</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lahiri</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Hempstead</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Brady</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cannon</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>Clark</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Condren</surname> <given-names>ME</given-names></name>, <etal>et al</etal>. <article-title>Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fibrosis</article-title>. <source>Pediatrics</source>. <year>2016</year>;<fpage>137</fpage>(<issue>4</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1542/peds.2015-1784" xlink:type="simple">10.1542/peds.2015-1784</ext-link></comment> <object-id pub-id-type="pmid">27009033</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref020"><label>20</label><mixed-citation publication-type="book" xlink:type="simple"><collab>World Health Organization</collab>-. <source>Physical Status: The use and interpretation of anthropometry</source>. In: <publisher-name>World Health Organization</publisher-name>, editor. <publisher-loc>Geneva</publisher-loc><year>1995</year>. <fpage>460</fpage> p.</mixed-citation></ref>
<ref id="pone.0198457.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fagerberg</surname> <given-names>UL</given-names></name>, <name name-style="western"><surname>Loof</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Merzoug</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Hansson</surname> <given-names>LO</given-names></name>, <name name-style="western"><surname>Finkel</surname> <given-names>Y</given-names></name>. <article-title>Fecal calprotectin levels in healthy children studied with an improved assay. Journal of pediatric gastroenterology and nutrition</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2003</year>;<volume>37</volume>(<issue>4</issue>):<fpage>468</fpage>–<lpage>72</lpage>. <object-id pub-id-type="pmid">14508218</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Swidsinski</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Loening-Baucke</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Verstraelen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Osowska</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Doerffel</surname> <given-names>Y</given-names></name>. <article-title>Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea</article-title>. <source>Gastroenterology</source>. <year>2008</year>;<volume>135</volume>(<issue>2</issue>):<fpage>568</fpage>–<lpage>79</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1053/j.gastro.2008.04.017" xlink:type="simple">10.1053/j.gastro.2008.04.017</ext-link></comment> <object-id pub-id-type="pmid">18570896</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Daims</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bruhl</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Amann</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Schleifer</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Wagner</surname> <given-names>M</given-names></name>. <article-title>The domain-specific probe EUB338 is insufficient for the detection of all Bacteria: development and evaluation of a more comprehensive probe set</article-title>. <source>Syst Appl Microbiol.</source> <year>1999</year>;<volume>22</volume>(<issue>3</issue>):<fpage>434</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0723-2020(99)80053-8" xlink:type="simple">10.1016/S0723-2020(99)80053-8</ext-link></comment> <object-id pub-id-type="pmid">10553296</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burke</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Fouhy</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Harrison</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Rea</surname> <given-names>MC</given-names></name>, <name name-style="western"><surname>Cotter</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>O'Sullivan</surname> <given-names>O</given-names></name>, <etal>et al</etal>. <article-title>The altered gut microbiota in adults with cystic fibrosis</article-title>. <source>BMC Microbiology</source>. <year>2017</year>;<volume>17</volume>(<issue>1</issue>):<fpage>58</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12866-017-0968-8" xlink:type="simple">10.1186/s12866-017-0968-8</ext-link></comment> <object-id pub-id-type="pmid">28279152</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schippa</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Iebba</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Santangelo</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Gagliardi</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>De Biase</surname> <given-names>RV</given-names></name>, <name name-style="western"><surname>Stamato</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients</article-title>. <source>PLOS ONE</source>. <year>2013</year>;<volume>8</volume>(<issue>4</issue>):<fpage>e61176</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0061176" xlink:type="simple">10.1371/journal.pone.0061176</ext-link></comment> <object-id pub-id-type="pmid">23613805</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Madan</surname> <given-names>JC</given-names></name>, <name name-style="western"><surname>Koestle</surname> <given-names>DC</given-names></name>, <name name-style="western"><surname>Stanton</surname> <given-names>BA</given-names></name>, <name name-style="western"><surname>Davidson</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Moulton</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Housman</surname> <given-names>ML</given-names></name>, <etal>et al</etal>. <article-title>Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: Interaction between intestinal and respiratory tracts and impact of nutritional exposures</article-title>. <source>mBio</source>. <year>2012</year>;<volume>3</volume>(<issue>4</issue>): <fpage>E00251</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mBio.00251-12" xlink:type="simple">10.1128/mBio.00251-12</ext-link></comment> <object-id pub-id-type="pmid">22911969</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Russell</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Ross</surname> <given-names>RP</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname> <given-names>GF</given-names></name>, <name name-style="western"><surname>Stanton</surname> <given-names>C</given-names></name>. <article-title>Metabolic activities and probiotic potential of bifidobacteria</article-title>. <source>Int J Food Microbiol</source>. <year>2011</year>;<volume>149</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>105</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijfoodmicro.2011.06.003" xlink:type="simple">10.1016/j.ijfoodmicro.2011.06.003</ext-link></comment> <object-id pub-id-type="pmid">21763022</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Flint</surname> <given-names>HJ</given-names></name>, <name name-style="western"><surname>Scott</surname> <given-names>KP</given-names></name>, <name name-style="western"><surname>Louis</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Duncan</surname> <given-names>SH</given-names></name>. <article-title>The role of the gut microbiota in nutrition and health</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2012</year>;<volume>9</volume>(<issue>10</issue>):<fpage>577</fpage>–<lpage>89</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrgastro.2012.156" xlink:type="simple">10.1038/nrgastro.2012.156</ext-link></comment> <object-id pub-id-type="pmid">22945443</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yasmin</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Tun</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Konya</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Guttman</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Chari</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Field</surname> <given-names>CJ</given-names></name>, <etal>et al</etal>. <article-title>Cesarean section, formula feeding, and infant antibiotic exposure: separate and combined impacts on gut microbial changes in later infancy</article-title>. <source>Front Pediatr</source>. <year>2017</year>;<volume>5</volume>:<fpage>200</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fped.2017.00200" xlink:type="simple">10.3389/fped.2017.00200</ext-link></comment> <object-id pub-id-type="pmid">29018787</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Azad</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Konya</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Persaud</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Guttman</surname> <given-names>DS</given-names></name>, <name name-style="western"><surname>Chari</surname> <given-names>RS</given-names></name>, <name name-style="western"><surname>Field</surname> <given-names>CJ</given-names></name>, <etal>et al</etal>. <article-title>Impact of maternal intrapartum antibiotics, method of birth and breastfeeding on gut microbiota during the first year of life: a prospective cohort study</article-title>. <source>BJOG</source>. <year>2016</year>;<volume>123</volume>(<issue>6</issue>):<fpage>983</fpage>–<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/1471-0528.13601" xlink:type="simple">10.1111/1471-0528.13601</ext-link></comment> <object-id pub-id-type="pmid">26412384</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dhaliwal</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Leach</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Katz</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Nahidi</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Pang</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>Intestinal inflammation and impact on growth in children with cystic fibrosis</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2015</year>;<volume>60</volume>(<issue>4</issue>):<fpage>521</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/MPG.0000000000000683" xlink:type="simple">10.1097/MPG.0000000000000683</ext-link></comment> <object-id pub-id-type="pmid">25539196</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weiss</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Bujanover</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Yahav</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Vilozni</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Fireman</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Efrati</surname> <given-names>O</given-names></name>. <article-title>Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study</article-title>. <source>Pediatr Pulmonol</source>. <year>2010</year>;<volume>45</volume>(<issue>6</issue>):<fpage>536</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ppul.21138" xlink:type="simple">10.1002/ppul.21138</ext-link></comment> <object-id pub-id-type="pmid">20503277</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Duytschaever</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Huys</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Bekaert</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Boulanger</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>De Boeck</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Vandamme</surname> <given-names>P</given-names></name>. <article-title>Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings</article-title>. <source>Appl Environ Microbiol</source>. <year>2011</year>;<volume>77</volume>(<issue>22</issue>):<fpage>8015</fpage>–<lpage>24</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AEM.05933-11" xlink:type="simple">10.1128/AEM.05933-11</ext-link></comment> <object-id pub-id-type="pmid">21926193</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hoffman</surname> <given-names>LR</given-names></name>, <name name-style="western"><surname>Pope</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Hayden</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Heltshe</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Levy</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>McNamara</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with cystic fibrosis</article-title>. <source>Clin infect Dis</source>. <year>2014</year>;<volume>58</volume>(<issue>3</issue>):<fpage>396</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/cit715" xlink:type="simple">10.1093/cid/cit715</ext-link></comment> <object-id pub-id-type="pmid">24178246</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Lisle</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Borowitz</surname> <given-names>D</given-names></name>. <source>The cystic fibrosis intestine</source>. <source>Cold Spring Harb Perspect Med</source>. <year>2013</year>;<fpage>3</fpage>(9). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/cshperspect.a009753" xlink:type="simple">10.1101/cshperspect.a009753</ext-link></comment></mixed-citation></ref>
<ref id="pone.0198457.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burke</surname> <given-names>DG</given-names></name>, <name name-style="western"><surname>Harrison</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Fleming</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>McCarthy</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Shortt</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sulaiman</surname> <given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection</article-title>. <source>J Cyst Fibros</source>. <year>2017</year>;<volume>16</volume>(<issue>2</issue>):<fpage>291</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcf.2016.09.008" xlink:type="simple">10.1016/j.jcf.2016.09.008</ext-link></comment> <object-id pub-id-type="pmid">27908697</object-id></mixed-citation></ref>
<ref id="pone.0198457.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leffler</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Lamont</surname> <given-names>JT</given-names></name>. <article-title>Clostridium difficile infection</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>16</issue>):<fpage>1539</fpage>–<lpage>48</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMra1403772" xlink:type="simple">10.1056/NEJMra1403772</ext-link></comment> <object-id pub-id-type="pmid">25875259</object-id>.</mixed-citation></ref>
<ref id="pone.0198457.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kerckhoffs</surname> <given-names>APM</given-names></name>, <name name-style="western"><surname>Ben-Amor</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Samsom</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>van Der Rest</surname> <given-names>ME</given-names></name>, <name name-style="western"><surname>De Vogel</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Knol</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome</article-title>. <source>J Med Microbiol</source>. <year>2011</year>;<volume>60</volume>(<issue>2</issue>):<fpage>236</fpage>–<lpage>45</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1099/jmm.0.022848–0" xlink:type="simple">10.1099/jmm.0.022848–0</ext-link></comment></mixed-citation></ref>
</ref-list>
</back>
</article>